Neuphoria Therapeutics Inc (NEUP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.98-0.33%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NEUP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-11-04 · Compared with 66 industry peers
NEUP — capital allocation — Material
Dated 2026-10-23
Material Modifications to Rights of Security Holders. The information set forth under
Why it matters: The merger needs at least $75 million in financing and a Nasdaq listing. Closing would support the planned Phase 3 trial.
Supportive ifThe companies report at least $75 million in secured financing. Nasdaq approves the listing, and the US Listing Transactions close.
Worry ifFinancing stays below $75 million. Nasdaq or SEC review blocks the listing, or the merger misses the February 28, 2027 end date without an extension.
Why it matters: CVR holders receive cash only if named partner, asset sale, or tax credit events bring in proceeds. No payment is assured.
Supportive ifScancell reports proceeds from a Merck, Pfizer-linked KAT6, or other covered asset deal, or from the Australian R&D tax credit. It says CVR holders are due a share.
Worry ifScancell reports no proceeds from covered partner deals, asset sales, or the tax credit. It says no CVR cash payment is due.
Why it matters: More survival data will test the results behind the planned Phase 3 trial. The company said it expects more data within 12 months.
Watch forThe next SCOPE update shows progression-free survival of at least 77% at 22 months. It also reports overall survival data.
Also watch forThe update shows progression-free survival below 77% at 22 months. Or it reports worse overall survival results than the prior data.
Why it matters: The merger requires Neuphoria to keep at least $10 million in cash. Falling below that level could block closing.
Worry ifAt closing, the companies report Neuphoria net cash of at least $10 million.
Less concerning ifThe companies report Neuphoria has less than $10 million in net cash at closing. Or they say this condition is unmet.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$104 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $492 loss on $10,000 · 4.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,562 loss on $10,000 · 45.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.